Clinical area · Cardiology

The stent was placed, the drug prescribed. But the drug was never activated.

Clopidogrel starts as an inactive prodrug; the enzyme that activates it is CYP2C19. If the enzyme is weak, the antiplatelet effect does not occur, and the greatest risk is stent thrombosis.

Prepared by the BIODECODE science team · Last updated: October 2026 · Based on CPIC, DPWG, FDA and peer-reviewed publications

In brief

  • Clopidogrel is one of the most widely used drugs for preventing clots after a stent. But it enters the body inactive and must be activated by the CYP2C19 enzyme.
  • In people whose CYP2C19 enzyme is genetically weak, the drug is not activated enough. Their risk of stent thrombosis and heart attack increases.
  • In cardiology, genetic differences affect more than clopidogrel: they also shape the muscle side effects of statins and the dose needed for warfarin.

Key concepts

Prodrug

A drug taken in inactive form that only works after an enzyme converts it. Clopidogrel is a prodrug.

Metabolizer type

Describes how fast an enzyme works genetically: poor, intermediate, normal, rapid and ultrarapid.

Stent thrombosis

A clot forming inside the metal mesh tube (stent) placed in a narrowed artery. It is a serious event that can cause a sudden heart attack.

Statin myopathy

Muscle pain and weakness that cholesterol drugs occasionally cause. In very rare cases it can progress to severe muscle breakdown.

How does clopidogrel work?

  1. The drug is taken inactive

    When clopidogrel reaches the liver, it cannot yet act on the platelets.

  2. CYP2C19 activates it

    The liver enzyme CYP2C19 converts the drug into its active form, which can bind to platelets.

  3. Platelets cannot stick together

    The active drug stops platelets clumping and prevents a clot inside the stent. If the enzyme is weak, this final step does not happen.

What does a CYP2C19 result mean for clopidogrel?

Metabolizer typeWhat happens?General guideline recommendation*
Ultrarapid, rapid, normalThe drug is activated as expected.Clopidogrel can be used at the standard dose.
IntermediateThe drug is activated less; protection is reduced.An alternative antiplatelet drug is recommended.
PoorThe drug is barely activated; protection is markedly reduced.An alternative antiplatelet drug is recommended.

* CPIC recommendation for patients receiving a stent for acute coronary syndrome. Recommendations may differ in other clinical settings.

Who is it relevant for?

  • Patients about to receive, or who have just received, a stent for acute coronary syndrome
  • Patients who had a new arterial blockage while on clopidogrel
  • People about to start a statin, or who had muscle symptoms on a statin
  • Patients about to start warfarin

Your physician decides whether the test is right for you.

Evidence

  • 30–70%

    Share of people carrying at least one CYP2C19*2 loss-of-function allele: up to 30% in European and African ancestry, up to 70% in Asian ancestry

    Clinical pharmacogenetics reviews
  • 1.75×

    Stent thrombosis risk in loss-of-function carriers; 14 additional events per 1,000

    Meta-analysis, Holmes et al.
  • 2010

    FDA boxed warning on the clopidogrel label: diminished effectiveness in poor metabolizers

    FDA
  • CPIC

    An alternative antiplatelet agent is recommended for intermediate and poor metabolizers with ACS undergoing PCI

    CPIC guideline

Related genes and drugs

GeneRoleRelated drugsSource
CYP2C19Liver enzyme that activates clopidogrelClopidogrelCPIC
SLCO1B1Gateway protein that carries statins into liver cellsSimvastatin, atorvastatin, rosuvastatin, pravastatin, pitavastatin, lovastatin, fluvastatinCPIC
ABCG2Transporter that pumps certain drugs out of cellsRosuvastatinCPIC
CYP2C9 · VKORC1 · CYP4F2Genes that set warfarin breakdown and the body's sensitivity to itWarfarinCPIC
CYP2D6Enzyme that processes many cardiovascular drugsMetoprololCPIC

What you will see in the BIODECODE report

  • *2 and *17

    CYP2C19 loss-of-function and increased-function alleles are assessed together.

  • Statins

    A separate SLCO1B1 verdict for each statin; myopathy risk and dose limits with source text.

  • Warfarin

    CYP2C9, VKORC1 and CYP4F2 are reported together as inputs to the dosing algorithm.

  • Cardiology section

    Every drug card shows the verdict, source gene and full guideline text.

Sample report (PDF)

Good to know

  • Genotype alone does not decide. Age, diabetes, kidney function and concomitant drugs also affect drug response.
  • Some stomach-protecting drugs suppress CYP2C19 and can reduce clopidogrel's effect. This is flagged separately in the pharmacogenomic report.
  • For statins and warfarin, genotype is used as part of the clinical algorithms that guidelines recommend.

Frequently asked questions

Should everyone taking clopidogrel be tested?

That is your physician's decision. CPIC recommendations matter especially for patients receiving a stent for acute coronary syndrome, where genotype can directly change the choice of antiplatelet drug.

I have my result; can I change my medicine myself?

No. Never stop or change a medicine on your own; always review your results with your physician.

I had muscle pain on a statin. Does genetic testing explain it?

SLCO1B1 variants increase the risk of muscle side effects, especially with simvastatin. Testing can help explain the risk, but muscle pain has other causes too, so it should be assessed with your physician.

References

  1. Mega JL et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009.
  2. Holmes MV et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011.
  3. Lee CR et al. CPIC guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022.
  4. Cooper-DeHoff RM et al. CPIC guideline for SLCO1B1, ABCG2 and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin Pharmacol Ther. 2022.
  5. Johnson JA et al. CPIC guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017.
  6. US Food and Drug Administration (FDA). Clopidogrel prescribing information, boxed warning. 2010.

This page is for information only; diagnosis and treatment decisions belong to your physician. Never stop or change a medicine on your own.

All clinical areas